Cargando…
Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa
Utilization of clinical technology and mobile health (mHealth) is expanding globally. It is important to reflect on how their usage and application could translate in low- and middle-income country (LMIC) settings. With the exponential growth and advancements of mobile and wireless technologies, LMI...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392770/ https://www.ncbi.nlm.nih.gov/pubmed/32614724 http://dx.doi.org/10.1200/JGO.19.00191 |
_version_ | 1783564914313396224 |
---|---|
author | Mutebi, Miriam Bhatia, Rohini Salako, Omolola Rubagumya, Fidel Grover, Surbhi Hammad, Nazik |
author_facet | Mutebi, Miriam Bhatia, Rohini Salako, Omolola Rubagumya, Fidel Grover, Surbhi Hammad, Nazik |
author_sort | Mutebi, Miriam |
collection | PubMed |
description | Utilization of clinical technology and mobile health (mHealth) is expanding globally. It is important to reflect on how their usage and application could translate in low- and middle-income country (LMIC) settings. With the exponential growth and advancements of mobile and wireless technologies, LMICs are prime to adapt such technologies to potentially democratize and create solutions to health-related challenges. The role of these technologies in oncology clinical trials continues to expand. The lure of mHealth promises disruptive technology that may change the way clinical trials are designed and conducted in many settings. Its applicability in the African context is currently under consideration. Although potentially of expanding benefit, the role of these technologies requires careful and nuanced evaluation of the context in which they might be applied to harness their full potential, while mitigating possible harms or preventing further deepening of disparities within populations. Moreover, technology and digital innovations are no substitute for poor referral pathways and dysfunctional health systems and can only complement or enhance definite strategies aimed at strengthening these health systems. |
format | Online Article Text |
id | pubmed-7392770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73927702020-08-03 Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa Mutebi, Miriam Bhatia, Rohini Salako, Omolola Rubagumya, Fidel Grover, Surbhi Hammad, Nazik JCO Glob Oncol REVIEW ARTICLES Utilization of clinical technology and mobile health (mHealth) is expanding globally. It is important to reflect on how their usage and application could translate in low- and middle-income country (LMIC) settings. With the exponential growth and advancements of mobile and wireless technologies, LMICs are prime to adapt such technologies to potentially democratize and create solutions to health-related challenges. The role of these technologies in oncology clinical trials continues to expand. The lure of mHealth promises disruptive technology that may change the way clinical trials are designed and conducted in many settings. Its applicability in the African context is currently under consideration. Although potentially of expanding benefit, the role of these technologies requires careful and nuanced evaluation of the context in which they might be applied to harness their full potential, while mitigating possible harms or preventing further deepening of disparities within populations. Moreover, technology and digital innovations are no substitute for poor referral pathways and dysfunctional health systems and can only complement or enhance definite strategies aimed at strengthening these health systems. American Society of Clinical Oncology 2020-07-02 /pmc/articles/PMC7392770/ /pubmed/32614724 http://dx.doi.org/10.1200/JGO.19.00191 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | REVIEW ARTICLES Mutebi, Miriam Bhatia, Rohini Salako, Omolola Rubagumya, Fidel Grover, Surbhi Hammad, Nazik Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title | Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title_full | Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title_fullStr | Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title_full_unstemmed | Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title_short | Innovative Use of mHealth and Clinical Technology for Oncology Clinical Trials in Africa |
title_sort | innovative use of mhealth and clinical technology for oncology clinical trials in africa |
topic | REVIEW ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392770/ https://www.ncbi.nlm.nih.gov/pubmed/32614724 http://dx.doi.org/10.1200/JGO.19.00191 |
work_keys_str_mv | AT mutebimiriam innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica AT bhatiarohini innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica AT salakoomolola innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica AT rubagumyafidel innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica AT groversurbhi innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica AT hammadnazik innovativeuseofmhealthandclinicaltechnologyforoncologyclinicaltrialsinafrica |